baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ocuphire Pharma Inc/ US67577R1023 /

20/09/2024 21:59:41	Chg. -0.07	Volume	Bid-	Ask-	High	Low
1.39USD	-4.81%	2,009 Turnover: 2,802.16	-Bid Size: -	-Ask Size: -	1.41	1.38

GlobeNewswire 13/08 Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

GlobeNewswire 08/08 Ocuphire Pharma to Present at Two Investor Conferences in August

GlobeNewswire 10/07 Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

GlobeNewswire 06/06 Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Re...

GlobeNewswire 10/05 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire 06/05 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

GlobeNewswire 03/05 Ocuphire Pharma to Present at the Aegis Virtual Conference

GlobeNewswire 22/04 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

GlobeNewswire 11/04 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...

GlobeNewswire 01/04 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...

GlobeNewswire 08/03 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...

GlobeNewswire 23/02 Ocuphire Pharma to Present in the BIO CEO & Investor Conference

GlobeNewswire 15/02 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 14/02 Ocuphire Pharma Strengthens Leadership Team with Key Appointments

GlobeNewswire 05/02 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...

GlobeNewswire 24/01 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 04/01 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...

GlobeNewswire 30/11/2023 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

GlobeNewswire 27/11/2023 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 27/11/2023 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

GlobeNewswire 13/11/2023 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

GlobeNewswire 02/11/2023 Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Re...

GlobeNewswire 01/11/2023 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01/11/2023 Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Offi...

GlobeNewswire 26/10/2023 Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

Ocuphire Pharma Inc/ US67577R1023 /

If you wish to receive reply to your feedback, please provide your email address.